Last reviewed · How we verify
Brinzolamide/Brimonidine FC
This fixed combination reduces intraocular pressure by inhibiting carbonic anhydrase (brinzolamide) and activating alpha-2 adrenergic receptors (brimonidine).
This fixed combination reduces intraocular pressure by inhibiting carbonic anhydrase (brinzolamide) and activating alpha-2 adrenergic receptors (brimonidine). Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | Brinzolamide/Brimonidine FC |
|---|---|
| Also known as | SIMBRINZA (brinzolamide/brimonidine 1%/0.2%), Alcon Lab. Ltd |
| Sponsor | University Hospital of Patras |
| Drug class | Carbonic anhydrase inhibitor / Alpha-2 adrenergic agonist combination |
| Target | Carbonic anhydrase II; Alpha-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Brinzolamide decreases aqueous humor production by inhibiting carbonic anhydrase in the ciliary body. Brimonidine is an alpha-2 adrenergic agonist that both reduces aqueous humor production and increases uveoscleral outflow. Together, these complementary mechanisms provide additive IOP-lowering effects.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Ocular hyperemia
- Blurred vision
- Ocular discomfort
- Taste perversion
- Allergic conjunctivitis
Key clinical trials
- Brinzolamide/Brimonidine Combination vs Brimonidine 0.2% in the Prevention of IOP Rise After Nd-YAG Laser Capsulotomy (PHASE4)
- Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension (PHASE3)
- Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Brinzolamide/Brimonidine FC CI brief — competitive landscape report
- Brinzolamide/Brimonidine FC updates RSS · CI watch RSS
- University Hospital of Patras portfolio CI